For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the May 30 issue of the New England Journal of Medicine. Thierry Facon, M.D., from the University of Lille in France, and colleagues...Continue Reading